tipifarnib has been researched along with Nausea in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D | 1 |
| Abbruzzese, JL; Giguere, JK; Iqbal, S; Macdonald, JS; McCoy, S; Wade, JL; Whitehead, RP | 1 |
| Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J | 1 |
| Bol, CJ; Punt, CJ; Seifert, WF; van Maanen, L; Wagener, DJ | 1 |
| Beijnen, JH; Boerrigter, L; Bol, CJ; Crul, M; de Gast, GC; de Jong, D; de Klerk, GJ; Palmer, PA; Schellens, JH; Swart, M; Tan, H; van't Veer, LJ | 1 |
5 trial(s) available for tipifarnib and Nausea
| Article | Year |
|---|---|
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Proto-Oncogene Mas; Quinolones; Survival Rate; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Anemia; Biological Availability; Bone Marrow; Capsules; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Half-Life; Headache; Humans; Hypotension; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Peripheral Nervous System Diseases; Quinolones; Solutions; Vomiting | 2000 |
Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Biological Availability; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Quinolones; Time Factors; Vomiting | 2001 |
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Antineoplastic Agents; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Genes, ras; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Nausea; Neoplasms; Quinolones; Vomiting | 2002 |